Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...
Berger has participated in meetings (lectures, advisory boards, consultations) sponsored and compensated by pharmaceutical ...
To this day, animal testing remains one of the most controversial issues in animal rights. Activists have been fighting ...
Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...
Sanofi's amlitelimab confirms its potential in atopic dermatitis: Paris Saturday, January 24, 2026, 10:00 Hrs [IST] Following the positive COAST 1 (clinical study identifier: NCT0 ...
This biotech small-cap's grown its dividend by 140% since 2016! So with an 8.3% yield, is now the time to add it to my Stocks ...
Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended ...
In January 2026, Vir Biotechnology reported new positive data from its ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta, where combination therapy with investigational agents tobevibart and ...
As of Friday, January 23, Jade Biosciences, Inc.’s JBIO share price has dipped by 5.64%, which has investors questioning if ...
The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...
Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results